Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
119 hedge funds and large institutions have $1.28B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2018 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 44 increasing their positions, 26 reducing their positions, and 10 closing their positions.
260% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 10
201% more capital invested
Capital invested by funds: $427M → $1.28B (+$858M)
133% more funds holding in top 10
Funds holding in top 10: 3 → 7 (+4)
69% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 26
68% more call options, than puts
Call options by funds: $11.6M | Put options by funds: $6.87M
28% more funds holding
Funds holding: 93 → 119 (+26)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$47.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$41.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$38.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35.9M |
| 5 |
BlackRock
New York
|
+$29.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$22.2M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$12.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.51M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$5.09M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$3.38M |
RETA Hedge Fund Activity: Q3 2018 in Review
119 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q3 2018, worth a combined $1.28B — up 201% from $427M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new RETA positions and 10 closed out — a net gain of 26 holders — while 44 added to existing stakes and 26 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $47.5M. The largest seller was Deerfield Management, cutting an estimated $22.2M.
- 119 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q3 2018, up from 93 in Q2 2018.
- Funds reported $1.28B of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q3 2018, up 201% quarter-over-quarter.
- 36 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q3 2018 and 10 closed out, a net change of +26 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q3 2018 was Farallon Capital Management, an estimated $47.5M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q3 2018 was Deerfield Management, an estimated $22.2M sold.
Based on aggregated 13F filings for Q3 2018.